JPS62106015A - 抗痴呆薬 - Google Patents

抗痴呆薬

Info

Publication number
JPS62106015A
JPS62106015A JP60245726A JP24572685A JPS62106015A JP S62106015 A JPS62106015 A JP S62106015A JP 60245726 A JP60245726 A JP 60245726A JP 24572685 A JP24572685 A JP 24572685A JP S62106015 A JPS62106015 A JP S62106015A
Authority
JP
Japan
Prior art keywords
threo
demential
dops
dementia
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP60245726A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0227327B2 (https=
Inventor
Mitsuo Yoshida
吉田　充男
Yoshikuni Mizuno
水野　美邦
Natsue Shimizu
清水　夏絵
Mieko Kumagai
熊谷　美恵子
Masakatsu Doubutsu
道佛　雅克
Yusuke Furukawa
雄祐 古川
Yutaka Shiroshita
城下　裕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Priority to JP60245726A priority Critical patent/JPS62106015A/ja
Priority to US06/857,239 priority patent/US4690949A/en
Priority to CA000508659A priority patent/CA1267094A/en
Publication of JPS62106015A publication Critical patent/JPS62106015A/ja
Publication of JPH0227327B2 publication Critical patent/JPH0227327B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP60245726A 1985-10-31 1985-10-31 抗痴呆薬 Granted JPS62106015A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP60245726A JPS62106015A (ja) 1985-10-31 1985-10-31 抗痴呆薬
US06/857,239 US4690949A (en) 1985-10-31 1986-04-29 Therapeutic drug for dementia
CA000508659A CA1267094A (en) 1985-10-31 1986-05-07 Therapeutic drug for dementia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60245726A JPS62106015A (ja) 1985-10-31 1985-10-31 抗痴呆薬

Publications (2)

Publication Number Publication Date
JPS62106015A true JPS62106015A (ja) 1987-05-16
JPH0227327B2 JPH0227327B2 (https=) 1990-06-15

Family

ID=17137887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60245726A Granted JPS62106015A (ja) 1985-10-31 1985-10-31 抗痴呆薬

Country Status (3)

Country Link
US (1) US4690949A (https=)
JP (1) JPS62106015A (https=)
CA (1) CA1267094A (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0269581A (ja) * 1988-09-05 1990-03-08 Sanmitsuku Tsusho Kk 遠赤外線放射性インキ組成物
JP3764179B2 (ja) * 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
ATE518540T1 (de) * 1999-08-16 2011-08-15 Revaax Pharmaceuticals Llc Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) * 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
WO2008003028A2 (en) * 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
ES2500053T3 (es) * 2007-03-09 2014-09-29 Chelsea Therapeutics, Inc. Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
JP2010526820A (ja) * 2007-05-07 2010-08-05 チェルシー・セラピューティクス，インコーポレイテッド 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
CN102413814A (zh) * 2009-04-29 2012-04-11 瑞恩药品公司 用于神经保护和治疗神经变性病症的克拉维酸类物质制剂
WO2010132128A1 (en) * 2009-05-14 2010-11-18 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
EP2764863B1 (en) * 2011-10-03 2020-03-11 National Center for Geriatrics and Gerontology Tau aggregation inhibitor
EP2962687B1 (en) 2013-04-02 2019-06-05 The Doshisha Tau aggregation inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920728A (en) * 1973-08-22 1975-11-18 Hoffmann La Roche Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine
JPS56104815A (en) * 1980-01-23 1981-08-20 Sumitomo Chem Co Ltd Remedy for peripheral orthostatic hypotension
JPS6067420A (ja) * 1983-09-22 1985-04-17 Sumitomo Chem Co Ltd 精神運動興奮抑制剤
US4499726A (en) * 1983-12-06 1985-02-19 United Stirling Ab Heater head for a multi-cylinder hot gas engine

Also Published As

Publication number Publication date
CA1267094A (en) 1990-03-27
US4690949A (en) 1987-09-01
JPH0227327B2 (https=) 1990-06-15

Similar Documents

Publication Publication Date Title
Mawdsley Treatment of Parkinsonism with Laevo-dopa
SWEET et al. Mental symptoms in Parkinson's disease during chronic treatment with levodopa
Price et al. dl-Glutamic acid hydrochloride in treatment of petit mal and psychomotor seizures
US20190321342A1 (en) Methods of treating developmental disorders with gaboxadol
JPS62106015A (ja) 抗痴呆薬
Preston et al. Effects of cocaine alone and in combination with mazindol in human cocaine abusers.
JP2010275314A (ja) 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
HUE026484T2 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
MX2012001814A (es) Uso de 4-aminopiridina para mejorar la discapacidad neuro - cognoscitiva y/o neuro - psiquiatrica en pacientes con condiciones desmielizantes y otras condiciones del sistema nervioso.
Newhouse et al. Stimulant drug effects on performance and behavior after prolonged sleep deprivation: a comparison of amphetamine, nicotine, and deprenyl
US3940485A (en) Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
JP3162709B2 (ja) 抗ストレス、ストレス予防性及び向神経性作用の医薬調製物
RU2025124C1 (ru) Антистрессорное, стресспротекторное, ноотропное средство, способ профилактики и лечения стрессовых состояний и способ повышения умственной работоспособности
US4735968A (en) Method of treating tinnitus with AOAA
Begemann et al. Treatment of refractory complex‐partial status epilepticus with propofol: case report
JP4276779B2 (ja) 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
US20220062265A1 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
EP3490550A1 (en) A2-73 as a therapeutic for insomnia, anxiety, and agitation
US6462089B1 (en) Method for correcting the vigilance disorders associated with myopathies
Sandyk A drug naive parkinsonian patient successfully treated with weak electromagnetic fields
JP2519148B2 (ja) うつ病治療剤
Godwin-Austen et al. Effect of age and arteriosclerosis on the response of Parkinsonian patients to levodopa
Praveen A Comparative Study to Evaluate the Efficacy and Safety of Levetiracetam as Add-On to Carbamazepine and Phenytoin in Focal Seizures at a Tertiary Care Hospital
RU2120283C1 (ru) Способ лечения эпилепсии
Manyam Practical guidelines for management of Parkinson disease